You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Merck
Baxter
Moodys
Express Scripts
McKesson

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Edaravone - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for edaravone and what is the scope of patent protection?

Edaravone is the generic ingredient in one branded drug marketed by Mitsubishi Tanabe and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Edaravone has seven patent family members in six countries.

Summary for edaravone
International Patents:7
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 139
Clinical Trials: 35
Patent Applications: 2,730
Formulation / Manufacturing:see details
DailyMed Link:edaravone at DailyMed
Recent Clinical Trials for edaravone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ruijin HospitalPhase 2
Auzone Biological Technology Pty LtdPhase 1
CMAX Clinical Research Pty LtdPhase 1

See all edaravone clinical trials

US Patents and Regulatory Information for edaravone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-001 May 5, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-002 Nov 15, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-001 May 5, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-001 May 5, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Mitsubishi Tanabe RADICAVA edaravone SOLUTION;INTRAVENOUS 209176-002 Nov 15, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Moodys
Colorcon
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.